102336Reducing Risk on the clinical pathway to PoC for a novel oral biologic for IBDClosedCollaborative R&DInnovate UKVHsquared Ltd is exploiting a pioneering oral domain antibody platform and validated low cost manufacturing process to bring a ground breaking inflammatory bowel disease (IBD) product to the market. This grant requests support for a first time in human trial of a novel, modified release, oral biologic formulation developed with the help of a previous TSB grant. The aim is to deliver maximum localised bioavailability of a potent biological therapy directly at the required site of action in the GI tract with minimal systemic exposure and immunogenicity. Current antibody therapies require parenteral administration, are expensive to manufacture, have safety concerns, and are subject to loss of response over time. VHsquared intends to harness the dramatic clinical impact of injectable antibody therapeutics directed against a well validated target in IBD and, by developing an oral alternative with a superior profile, benefit both patients and health care providers.